Brief: Paratek Pharmaceuticals Reports Q2 Loss Per Share $0.53
10/08/2020 14:19
Aug 10 (Reuters) - Paratek Pharmaceuticals Inc PRTK.O :
* PARATEK PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2020
TOTAL
REVENUE OF $9.3 MILLION INCLUDING NUZYRA® (OMADACYCLINE) NET
REVENUE OF $8.1 MILLION
* Q2 LOSS PER SHARE $0.53
* Q2 REVENUE ROSE 356 PERCENT TO $9.3 MILLION
* Q2 REVENUE ESTIMATE $38 MILLION -- REFINITIV IBES DATA
* Q2 EARNINGS PER SHARE ESTIMATE $-0.06 -- REFINITIV IBES
DATA
* RAISING ITS FULL YEAR 2020 REVENUE GUIDANCE
* PARATEK NOW ESTIMATES 2020 TOTAL REVENUE TO BE BETWEEN $78
AND
$83 MILLION
* FY2020 REVENUE VIEW $81.2 MILLION -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX2m471b
Further company coverage: PRTK.O
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million